{
    "ticker": "ADCT",
    "name": "Adicet Bio, Inc.",
    "description": "Adicet Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer and other serious diseases. Founded in 2015 and headquartered in South San Francisco, California, Adicet aims to harness the power of the immune system to create a new class of therapies that can effectively target and eliminate tumors. The company's proprietary technology platform, based on gamma delta T cells, enables the development of off-the-shelf cellular therapies that can be used to treat a wide range of cancers. Adicet's lead product candidate, ADI-001, is currently in clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies, showcasing promising potential in improving patient outcomes. With a strong focus on research and development, Adicet Bio is dedicated to advancing its pipeline and expanding its therapeutic applications while collaborating with leading institutions and partners in the biopharmaceutical industry. The company's mission is to deliver transformative therapies that can significantly improve the lives of patients battling cancer, ultimately contributing to the future of cancer treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.adicetbio.com",
    "ceo": "Chad Robins",
    "social_media": {
        "twitter": "https://twitter.com/AdicetBio",
        "linkedin": "https://www.linkedin.com/company/adicet-bio/"
    },
    "investor_relations": "https://investors.adicetbio.com",
    "key_executives": [
        {
            "name": "Chad Robins",
            "position": "CEO"
        },
        {
            "name": "Jennifer A. L. E. B. T. H. H. M. B. L. A. K. R.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "ADI-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Adicet Bio, Inc. | Innovative Cell Therapies for Cancer",
        "meta_description": "Explore Adicet Bio, Inc., a leader in developing innovative cell therapies to treat cancer. Learn about our mission and our clinical-stage product candidates.",
        "keywords": [
            "Adicet Bio",
            "Cell Therapies",
            "Cancer Treatment",
            "Biotechnology",
            "ADI-001"
        ]
    },
    "faq": [
        {
            "question": "What does Adicet Bio focus on?",
            "answer": "Adicet Bio focuses on developing cell therapies for the treatment of cancer and other serious diseases."
        },
        {
            "question": "Where is Adicet Bio headquartered?",
            "answer": "Adicet Bio is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is Adicet's lead product candidate?",
            "answer": "Adicet's lead product candidate is ADI-001, which is in clinical trials for B-cell malignancies."
        },
        {
            "question": "When was Adicet Bio founded?",
            "answer": "Adicet Bio was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "KITE",
        "ZIOP"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "JNJ"
    ]
}